Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"
AKT2		ENSG00000105221	"AKT serine/threonine kinase 2"	P31751	19	40230317-40285536	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Sugar transport, Translation regulation, Transport"	"Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Diabetes mellitus, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004204, HPA064521"	Uncertain		Supported	Nucleoplasm,Vesicles,Cytosol				"Nucleoplasm, Vesicles, Cytosol"		"CAB004204: AB_626659, HPA064521: "	"unprognostic (6.13e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.56e-1)"	"prognostic unfavourable (1.05e-6)"	"unprognostic (2.85e-1)"	"unprognostic (6.40e-3)"	"unprognostic (9.59e-2)"	"unprognostic (1.22e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.49e-2)"	"unprognostic (3.02e-1)"	"prognostic unfavourable (4.74e-4)"	"unprognostic (1.30e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.28e-1)"	"unprognostic (6.16e-2)"	"unprognostic (2.00e-1)"	31.1	20.3	15.4	17.6	15.2	21.3	18.2	46.3	18.2	23.3	18.2	23.4	21.2	12.3	22.8	28.0	22.1	22.7	14.0	23.1	15.4	10.0	23.0	62.5	14.6	17.8	17.9	13.3	27.8	24.5	21.1	24.0	17.5	14.7	19.7	12.3	26.8	18.5	24.3	48.5	18.3	17.1	20.0	16.8	18.7	15.5	21.3	15.7	26.6	52.6	29.5	23.6	19.6	19.9	6.3	8.8	7.7	4.4	3.2	4.9	2.4	22.4	55.4	21.1	21.7	26.3	32.2	11.7	15.0	22.2	31.1	27.8	24.3	20.9	22.9	13.4	33.1	9.8	23.4	31.3	20.1	21.9	26.7	15.0	35.1	15.3	16.5	17.2	18.1	29.7	18.8	21.1	20.1	6.7	19.3	24.0	17.3	18.7	27.3	8.4	11.4	14.9	18.2	11.5	16.5	24.2	36.8	29.1	17.8	15.4	26.4	12.5	20.8	22.2	6.7	19.0	18.8	17.0	23.5	22.4	19.2	18.8	18.6	20.4	15.5	7.6	4.4	3.6	4.5	2.0	4.5	3.9	3.6	3.0	3.0	6.3	3.5	4.9	7.7	3.2	2.6	8.8	2.7	2.4	15.4	15.2	46.3	18.2	15.4	10.0	17.9	13.3	14.7	15.7
ALK	CD246	ENSG00000171094	"ALK receptor tyrosine kinase"	Q9UM73	2	29192774-29921566	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 8.1;pituitary gland: 17.9"	"Cell line enriched"	"Detected in some"	6	"SH-SY5Y: 26.4"	"Group enriched"	"Detected in some"	5	"glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010694	Approved		Supported	"Plasma membrane"				"Plasma membrane"		"HPA010694: AB_1078133"	"unprognostic (4.96e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.56e-7)"	"unprognostic (7.17e-2)"	"unprognostic (1.71e-1)"	"unprognostic (9.07e-3)"	"unprognostic (6.29e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.67e-4)"	"unprognostic (3.70e-2)"	"unprognostic (2.06e-2)"	"unprognostic (7.15e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.61e-2)"	1.8	3.1	3.6	1.2	4.4	0.3	1.1	0.5	8.1	0.7	2.1	2.0	0.0	0.7	0.5	0.5	0.6	0.5	1.2	0.4	3.4	4.9	0.4	0.5	1.1	0.5	2.7	4.2	0.6	0.4	0.4	17.9	0.5	5.5	0.5	1.2	2.4	0.9	0.8	0.3	0.9	1.5	0.9	2.1	0.5	0.8	4.9	0.9	0.0	1.6	0.0	0.3	0.6	1.2	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	3.5	0.0	0.0	0.1	0.3	26.4	0.0	0.0	0.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	3.1	0.0	4.0	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	3.6	4.4	0.5	5.9	3.4	4.9	2.7	4.2	5.5	0.9
CCNE1	CCNE	ENSG00000105173	"Cyclin E1"	P24864	19	29811898-29824308	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 23.3;placenta: 46.7"	"Cell line enhanced"	"Detected in many"		"BEWO: 79.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB000308, CAB016682, HPA018169"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000308: , CAB016682: AB_1614564, HPA018169: AB_1847384"	"unprognostic (2.90e-3)"	"unprognostic (1.33e-2)"	"unprognostic (1.47e-3)"	"prognostic unfavourable (6.35e-6)"	"unprognostic (5.78e-2)"	"unprognostic (4.77e-2)"	"prognostic unfavourable (3.89e-5)"	"unprognostic (1.26e-3)"	"unprognostic (3.14e-3)"	"prognostic unfavourable (2.97e-4)"	"unprognostic (3.29e-2)"	"unprognostic (7.07e-2)"	"unprognostic (1.11e-16)"	"unprognostic (5.61e-2)"	"unprognostic (1.92e-1)"	"unprognostic (6.63e-2)"	"unprognostic (1.46e-1)"	1.6	6.8	2.4	4.5	2.9	23.3	0.6	6.3	3.3	0.8	3.0	1.7	1.1	2.3	1.2	0.6	4.7	0.7	2.2	4.4	2.3	2.8	1.2	0.7	1.1	4.6	1.9	1.9	0.9	1.4	1.7	1.0	46.7	2.8	1.1	3.8	1.5	3.2	1.2	2.2	4.4	2.5	3.0	1.7	4.6	2.0	12.3	1.6	4.1	1.6	2.1	5.9	2.7	2.5	2.7	1.6	1.6	1.9	0.0	1.4	0.5	4.0	8.4	6.5	9.2	1.4	1.6	79.9	6.5	1.4	2.9	3.5	8.5	8.2	3.4	15.3	2.8	1.2	7.6	3.3	4.1	10.8	4.7	2.9	8.2	8.9	1.1	11.3	7.7	1.6	1.8	3.9	0.5	3.5	11.6	1.5	4.3	6.0	6.2	3.2	10.8	2.0	9.3	7.6	2.6	2.2	6.5	5.5	4.6	9.3	11.5	1.0	2.5	8.4	2.0	6.7	25.4	4.0	4.3	6.5	4.5	23.4	3.8	1.4	3.6	0.0	0.1	0.0	0.6	1.9	1.1	2.7	0.5	0.4	1.6	0.2	0.1	0.9	1.6	0.0	1.9	0.0	1.4	0.5	2.4	2.9	6.3	3.3	2.3	2.8	1.9	1.9	2.8	1.6
DROSHA	"Etohi2, HSA242976, RN3, RNASE3L, RNASEN"	ENSG00000113360	"Drosha ribonuclease III"	Q9NRR4	5	31400497-31532196	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ribosome biogenesis, RNA-mediated gene silencing"	"Endonuclease, Hydrolase, Nuclease, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (8.37e-3)"	"unprognostic (1.81e-1)"	"unprognostic (9.56e-2)"	"prognostic unfavourable (6.79e-4)"	"unprognostic (5.40e-2)"	"unprognostic (6.03e-2)"	"prognostic unfavourable (1.39e-4)"	"unprognostic (3.11e-1)"	"unprognostic (4.08e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.86e-1)"	"unprognostic (5.43e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.74e-1)"	"unprognostic (2.39e-1)"	"unprognostic (6.94e-2)"	"unprognostic (2.32e-2)"	15.7	16.8	18.4	17.7	32.1	12.2	16.1	33.7	33.7	17.4	16.3	19.1	12.2	15.9	22.3	25.8	16.0	18.2	14.1	15.2	16.6	15.1	15.3	11.7	13.9	17.8	13.6	16.4	26.7	17.8	23.9	38.9	17.0	18.9	17.2	19.2	23.7	17.5	19.2	23.6	16.0	17.5	16.9	19.4	16.8	16.0	12.8	16.4	25.6	21.9	13.4	19.8	18.2	16.2	4.7	6.4	3.3	4.8	4.8	6.4	3.1	12.1	15.4	17.0	23.2	9.1	11.1	24.6	16.1	7.9	15.1	11.3	16.2	15.9	13.7	18.6	11.8	10.7	20.9	12.2	16.8	12.8	14.8	16.8	50.5	11.7	8.2	18.8	50.3	8.8	8.6	16.8	8.1	12.8	21.4	6.5	13.2	12.1	18.1	14.1	16.1	12.3	16.5	32.6	9.9	8.5	13.9	8.9	11.8	41.0	16.8	9.9	15.5	10.8	11.1	14.5	16.9	13.1	15.3	11.8	19.4	15.1	10.1	21.2	13.9	1.8	2.4	3.3	5.2	2.6	5.5	4.2	5.4	6.0	5.2	4.7	6.4	4.4	0.8	4.8	4.8	6.4	5.1	3.1	18.4	32.1	33.7	33.7	16.6	15.1	13.6	16.4	18.9	16.4
EGFR	"ERBB, ERBB1"	ENSG00000146648	"Epidermal growth factor receptor"	P00533	7	55019021-55211628	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Host-virus interaction"	"Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 102.3"	"Cell line enriched"	"Detected in many"	12	"A-431: 337.7"	"Cancer enhanced"	"Detected in all"		"glioma: 136.0"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534"	Enhanced		Enhanced	"Plasma membrane,Cell Junctions"	"Secreted to blood"		93000000	"Plasma membrane, Cell Junctions"		"CAB000035: , CAB068186: , CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044"	"unprognostic (2.62e-2)"	"unprognostic (9.56e-3)"	"unprognostic (1.59e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.27e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.88e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.30e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.98e-3)"	"unprognostic (1.72e-1)"	"unprognostic (6.62e-2)"	"prognostic unfavourable (2.04e-5)"	16.2	8.4	4.9	7.5	6.8	0.1	39.8	5.1	8.5	13.8	7.8	3.3	10.7	3.6	8.2	11.7	15.6	8.8	8.5	4.8	6.8	2.7	7.6	23.5	14.2	2.3	4.1	3.9	10.4	10.1	1.8	2.1	102.3	5.6	10.9	6.7	9.2	15.4	12.9	10.7	32.5	6.3	15.5	3.5	3.3	7.8	5.5	5.9	3.2	12.8	15.5	8.0	10.2	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	337.7	4.3	1.1	1.5	6.9	4.3	1.1	3.3	4.5	2.0	1.6	0.8	3.7	0.2	0.8	2.8	13.5	0.0	14.9	2.5	0.1	0.2	0.0	1.8	0.2	1.8	0.0	0.0	2.1	13.7	5.2	27.9	0.2	0.0	0.0	4.4	0.2	0.0	0.0	0.3	2.2	0.0	0.6	0.0	2.5	3.6	0.0	1.3	2.8	3.4	0.6	0.3	0.7	1.0	1.9	0.5	14.6	3.1	0.0	0.3	0.1	2.5	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	6.8	5.1	6.6	6.8	2.7	4.1	3.9	5.6	5.9
ERBB2	"CD340, HER-2, HER2, NEU, NGL"	ENSG00000141736	"Erb-b2 receptor tyrosine kinase 2"	P04626	17	39687914-39730426	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enriched"	"Detected in many"	27	"SK-BR-3: 263.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.8"	"Lineage enriched"	"Detected in many"	4	"T-cells: 8.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555"	Enhanced		Supported	"Plasma membrane,Cytosol"			430000	"Plasma membrane"	Cytosol	"CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: , HPA001060: , HPA001338: , HPA001383: AB_1078500"	"unprognostic (1.97e-1)"	"unprognostic (6.60e-3)"	"unprognostic (6.21e-2)"	"prognostic unfavourable (8.99e-8)"	"unprognostic (2.96e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.97e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.20e-3)"	"prognostic unfavourable (9.17e-4)"	"unprognostic (3.92e-1)"	"prognostic favourable (2.41e-14)"	"unprognostic (9.29e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.96e-1)"	5.8	2.4	5.2	10.4	7.0	0.1	20.1	4.2	7.0	19.1	46.5	9.1	55.2	21.6	14.9	18.7	40.9	22.7	26.6	24.8	6.3	3.1	37.5	21.5	17.6	3.7	5.1	5.6	19.3	16.2	27.7	8.1	60.8	7.5	23.6	16.6	15.9	28.7	58.1	8.9	35.3	47.2	10.9	4.5	4.0	17.1	6.5	3.7	2.8	35.7	20.8	22.9	19.7	20.3	1.3	0.3	2.1	0.4	0.9	8.8	2.2	3.1	3.8	4.2	2.7	5.1	3.6	5.7	2.2	3.7	4.9	4.2	2.8	8.6	0.2	4.6	5.1	9.8	0.2	5.1	2.3	0.4	3.2	0.1	3.0	4.5	3.0	0.0	0.0	3.5	4.8	3.0	1.8	2.0	0.4	0.1	3.6	4.8	0.5	0.2	7.6	0.9	0.3	1.7	0.4	5.0	9.8	0.8	0.2	4.2	263.9	1.3	7.4	0.1	0.2	2.5	3.3	3.2	1.4	0.4	0.2	0.2	0.2	0.0	8.2	1.6	0.4	0.8	8.8	0.3	0.7	0.9	0.5	2.5	0.3	1.3	1.0	2.5	2.1	0.9	0.2	0.2	0.4	2.2	5.2	7.0	4.2	7.0	6.3	3.1	5.1	5.6	7.5	3.7
ERG	"erg-3, p55"	ENSG00000157554	"ERG, ETS transcription factor"	P11308	21	38380027-38661780	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"HUVEC TERT2: 42.7;MOLT-4: 14.0;REH: 45.3;TIME: 34.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 18.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"myeloid DC: 1.7;NK-cell: 1.0"	"Group enriched"	"Detected in many"	5	"dendritic cells: 1.7;NK-cells: 1.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB018377, HPA046598"	Approved		Approved	Nucleoplasm,Cytosol				Nucleoplasm	Cytosol	"CAB018377: AB_675518, HPA046598: "	"unprognostic (2.14e-1)"	"prognostic unfavourable (6.18e-6)"	"unprognostic (6.44e-3)"	"unprognostic (8.64e-3)"	"unprognostic (5.65e-2)"	"unprognostic (1.91e-1)"	"unprognostic (9.03e-4)"	"unprognostic (4.30e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.42e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavourable (3.94e-4)"	"unprognostic (4.31e-3)"	"unprognostic (3.88e-2)"	"unprognostic (2.64e-2)"	"unprognostic (5.63e-3)"	39.1	4.2	5.7	6.5	8.5	6.6	20.5	3.6	7.0	17.9	5.2	2.3	5.6	3.3	16.9	9.0	6.2	9.2	11.6	10.1	6.2	3.6	10.8	6.0	19.9	7.4	8.0	1.8	7.7	4.8	2.3	3.9	23.2	8.0	8.1	3.6	7.8	4.2	5.6	13.5	5.3	6.2	11.8	4.7	32.5	5.0	4.8	5.0	2.4	10.8	9.1	3.6	9.6	15.8	0.0	1.7	0.0	0.2	1.0	0.0	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	7.0	0.0	0.0	0.3	0.0	42.7	0.0	0.0	0.0	0.3	14.0	0.0	0.1	0.0	45.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	34.6	0.2	0.7	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.4	5.7	8.5	3.6	7.0	6.2	3.6	8.0	1.8	8.0	5.0
FLT4	"PCL, VEGFR3"	ENSG00000037280	"Fms related tyrosine kinase 4"	P35916	5	180601506-180649624	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 56.3"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 8.3;BEWO: 10.2;HEK 293: 12.6;HL-60: 7.4;HUVEC TERT2: 8.1;T-47d: 12.0;TIME: 12.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"MAIT T-cell: 7.7"	"Lineage enriched"	"Detected in single"	35	"T-cells: 7.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000099, HPA046519, HPA067906"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	"Secreted to blood"		270000000	"Plasma membrane"	"Nucleoplasm, Cell Junctions"	"CAB000099: , HPA046519: , HPA067906: "	"unprognostic (7.35e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.45e-3)"	"unprognostic (3.81e-1)"	"unprognostic (9.26e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.69e-1)"	"unprognostic (1.88e-2)"	"unprognostic (9.41e-3)"	"unprognostic (1.83e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.32e-1)"	14.8	7.1	1.6	4.9	6.0	0.7	28.5	1.3	2.7	6.3	7.3	1.9	2.1	3.1	7.3	6.2	5.7	9.2	5.3	6.4	1.7	0.9	11.7	10.2	14.1	23.6	2.0	0.8	5.8	2.3	2.3	6.2	56.3	2.1	4.9	1.4	6.7	3.3	4.4	4.8	2.8	4.7	4.7	1.5	14.5	2.4	3.5	2.0	0.3	19.4	4.4	2.3	6.1	14.7	0.0	0.1	0.2	0.0	0.0	7.7	0.2	0.1	2.0	2.7	8.3	0.0	0.0	10.2	0.2	0.1	0.0	0.0	0.3	0.3	0.2	0.8	0.1	0.3	2.8	0.1	0.2	0.1	12.6	1.0	0.4	0.4	0.1	7.4	0.2	0.2	0.0	0.1	0.3	8.1	0.3	0.3	1.7	4.5	0.1	0.4	5.8	0.5	6.5	0.0	0.1	0.1	0.2	0.2	0.9	0.1	0.2	0.0	12.0	0.2	12.7	0.1	5.9	0.2	0.1	0.2	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.9	0.0	7.7	0.0	0.4	1.6	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.2	1.6	6.0	1.3	2.7	1.7	0.9	2.0	0.8	2.1	2.0
JUN	"AP-1, c-Jun"	ENSG00000177606	"Jun proto-oncogene, AP-1 transcription factor subunit"	P05412	1	58780788-58784327	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RH-30: 71.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB003801, CAB007780, HPA059474"	Enhanced		Enhanced	Nucleoplasm				Nucleoplasm		"CAB003801: AB_365485, CAB007780: AB_562268, HPA059474: "	"unprognostic (2.06e-2)"	"unprognostic (1.76e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.85e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.11e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.24e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.82e-1)"	"unprognostic (5.15e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.81e-3)"	64.5	29.4	26.7	33.7	17.2	68.4	61.7	19.5	20.6	60.0	32.7	30.8	28.4	13.3	40.5	21.8	34.1	72.6	48.5	31.3	20.2	12.4	21.2	39.3	55.1	14.3	15.3	12.0	49.8	48.7	15.0	16.7	21.6	24.1	48.6	16.7	40.5	59.4	39.3	32.2	51.3	28.6	40.7	17.6	22.9	47.0	18.2	18.1	9.0	61.0	35.2	23.3	41.5	33.1	7.4	1.3	4.0	5.1	3.2	2.5	1.2	16.0	2.3	5.2	1.0	8.3	9.4	0.1	20.5	7.5	14.5	8.8	4.2	1.2	0.6	9.9	12.7	5.6	0.4	6.6	9.2	12.7	37.3	0.2	0.9	4.7	6.8	1.1	3.7	10.1	17.1	18.7	7.8	10.8	5.6	9.3	5.6	3.0	1.0	9.0	4.1	14.6	0.4	71.1	3.2	13.6	1.5	14.4	4.2	14.2	14.9	6.0	5.3	0.6	19.0	33.1	15.0	12.0	25.6	20.7	3.3	1.2	34.5	2.1	9.4	1.2	5.1	2.0	2.4	1.1	1.3	4.1	1.2	2.5	1.3	7.4	0.3	1.7	4.0	3.2	0.4	0.2	0.9	1.2	26.7	17.2	19.5	20.6	20.2	12.4	15.3	12.0	24.1	18.1
KAT6A	"MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220"	ENSG00000083168	"Lysine acetyltransferase 6A"	Q92794	8	41929479-42051990	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase"	"Cancer-related genes, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017023, HPA063266, HPA065052"	Supported		Approved	"Nucleoli,Nuclear speckles,Cytosol"				"Nuclear speckles"	"Nucleoli, Cytosol"	"CAB017023: , HPA063266: , HPA065052: "	"unprognostic (3.51e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.04e-1)"	"unprognostic (3.23e-2)"	"unprognostic (2.28e-1)"	"unprognostic (9.27e-3)"	"unprognostic (3.61e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.95e-1)"	"unprognostic (2.45e-2)"	"unprognostic (1.50e-1)"	"unprognostic (4.45e-2)"	"unprognostic (4.20e-3)"	"unprognostic (1.18e-1)"	"unprognostic (2.24e-1)"	"unprognostic (8.58e-2)"	"unprognostic (2.95e-2)"	20.8	10.9	15.3	19.8	20.3	36.8	22.6	29.9	18.7	19.7	14.6	19.4	14.4	10.7	20.6	12.1	16.9	16.5	14.3	13.0	15.5	11.5	12.3	13.6	26.9	28.2	23.2	10.3	27.2	13.1	26.8	22.3	20.9	15.7	14.1	12.0	12.8	15.1	17.0	21.0	25.5	18.0	25.0	22.9	20.4	14.0	14.1	21.7	30.4	17.9	14.3	20.1	16.9	24.2	4.7	1.8	10.9	1.6	3.1	3.9	1.4	12.9	10.6	17.5	11.1	9.8	11.2	5.9	8.7	11.3	10.8	8.4	6.7	6.2	19.2	8.7	8.5	8.3	13.6	8.2	12.7	9.9	7.9	27.6	6.6	5.0	7.4	14.5	12.7	9.3	9.4	10.0	12.4	10.3	23.1	12.2	9.8	5.7	29.5	4.6	6.7	4.2	23.6	19.6	6.1	5.3	14.9	10.9	9.4	10.1	6.8	7.0	15.6	6.4	12.0	13.3	9.4	11.8	9.3	10.0	16.1	20.8	7.1	6.6	11.5	3.5	1.6	2.8	3.5	1.2	3.9	2.4	2.6	3.3	1.0	4.7	3.6	2.9	10.9	3.1	1.2	1.8	3.5	1.4	15.3	20.3	29.9	18.7	15.5	11.5	23.2	10.3	15.7	21.7
LMO1	"RBTN1, RHOM1, TTG1"	ENSG00000166407	"LIM domain only 1"	P25800	11	8224304-8268716	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	5	"retina: 29.4;skeletal muscle: 29.1"	"Cell line enhanced"	"Detected in some"		"HeLa: 21.2;SCLC-21H: 8.3;SH-SY5Y: 25.4;SiHa: 5.1"	"Cancer enriched"	"Detected in many"	6	"glioma: 6.4"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"														"unprognostic (3.74e-3)"	"unprognostic (1.45e-1)"		"unprognostic (4.75e-6)"	"unprognostic (9.34e-2)"	"unprognostic (2.37e-1)"		"unprognostic (1.98e-1)"	"unprognostic (7.06e-3)"	"unprognostic (8.09e-2)"	"unprognostic (2.24e-1)"	"unprognostic (9.05e-2)"	"unprognostic (4.36e-12)"	"unprognostic (1.76e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.58e-2)"	"unprognostic (3.13e-2)"	0.3	1.7	2.5	0.3	2.1	0.2	0.6	0.4	3.0	0.2	0.2	1.5	0.1	0.4	0.3	2.1	0.6	0.3	0.2	0.5	2.3	5.9	1.0	0.2	0.2	0.2	3.5	0.6	0.2	1.6	0.2	2.1	0.3	2.1	0.3	0.2	29.4	0.2	0.2	29.1	6.4	0.3	0.5	1.2	0.6	0.6	1.6	2.0	0.1	0.2	0.1	0.2	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.9	0.0	21.2	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.9	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	8.3	25.4	5.1	2.9	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.2	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.1	0.4	3.0	2.3	5.9	3.5	0.6	2.1	2.0
MDM2	"HDM2, MGC5370"	ENSG00000135679	"MDM2 proto-oncogene"	Q00987	12	68808176-68850686	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HBEC3-KT: 93.7;U-698: 90.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000086, CAB016303"	Supported		Supported	Nucleoplasm				Nucleoplasm		"CAB000086: AB_563872, CAB016303: AB_627920"	"unprognostic (1.16e-1)"	"prognostic favourable (3.23e-4)"	"unprognostic (6.16e-2)"	"prognostic favourable (4.51e-7)"	"unprognostic (7.25e-2)"	"unprognostic (6.91e-2)"	"unprognostic (3.77e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.45e-2)"	"unprognostic (3.23e-1)"	"unprognostic (1.80e-3)"	"unprognostic (2.36e-1)"	"unprognostic (4.22e-2)"	"unprognostic (4.59e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.68e-1)"	"unprognostic (8.95e-2)"	16.6	15.3	11.1	12.5	10.8	23.1	12.5	12.0	11.3	13.1	16.6	13.6	11.9	5.2	8.8	9.4	14.2	12.6	12.3	9.0	8.8	8.6	11.2	25.7	15.9	13.3	14.2	7.1	11.0	21.4	11.4	10.4	24.5	11.9	12.6	21.5	7.8	10.5	11.1	19.5	9.8	7.2	10.8	10.8	15.3	9.8	6.5	11.5	29.5	13.6	10.8	14.1	13.5	12.6	4.9	4.0	19.3	6.4	3.6	4.4	3.0	3.1	7.3	7.7	3.9	10.0	9.3	39.4	8.7	8.7	4.6	7.4	4.4	1.4	32.6	2.4	5.7	1.8	5.2	93.7	7.5	8.6	3.7	6.0	6.2	19.8	9.8	5.3	5.5	14.3	8.0	18.4	12.5	12.9	6.1	7.9	8.8	5.0	7.0	1.7	6.5	1.4	24.8	5.3	2.7	2.8	26.1	5.9	3.4	5.5	4.3	1.9	10.1	3.5	13.8	3.5	6.7	2.9	3.1	12.1	7.6	90.1	5.4	2.1	14.4	5.3	5.4	4.8	4.4	4.0	3.9	4.7	3.7	4.1	2.8	4.9	4.0	3.7	19.3	3.6	6.4	4.0	3.8	3.0	11.1	10.8	12.0	11.3	8.8	8.6	14.2	7.1	11.9	11.5
MDM4	"HDMX, MDMX"	ENSG00000198625	"MDM4, p53 regulator"	O15151	1	204516379-204558120	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"BEWO: 33.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018919, HPA048821"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA018919: AB_1853694, HPA048821: "	"unprognostic (4.63e-2)"	"unprognostic (3.73e-1)"	"unprognostic (6.38e-2)"	"unprognostic (1.50e-1)"	"unprognostic (3.84e-2)"	"unprognostic (1.68e-3)"	"unprognostic (2.33e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.51e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.17e-2)"	"prognostic unfavourable (9.87e-4)"	"prognostic unfavourable (7.06e-6)"	"unprognostic (1.20e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.49e-2)"	"prognostic favourable (2.49e-4)"	12.7	8.8	14.4	21.1	18.0	59.1	14.6	19.7	16.4	12.2	10.6	20.4	15.8	7.6	12.5	23.6	10.4	12.3	10.3	11.3	13.7	8.0	11.1	12.3	15.4	21.0	20.5	9.5	19.0	16.7	11.1	19.0	12.4	13.4	13.1	12.4	14.2	11.3	15.4	12.0	23.7	15.2	18.5	13.5	19.9	11.9	19.6	19.4	55.8	15.1	9.5	21.0	13.9	12.7	15.1	9.0	8.1	4.8	4.9	7.8	2.4	3.5	7.0	7.1	9.7	5.0	5.5	33.5	2.6	2.7	3.4	5.1	3.6	4.9	12.2	2.6	3.7	3.8	4.7	4.0	4.7	3.7	3.3	9.7	15.6	4.2	3.8	7.5	9.6	5.6	2.6	5.6	10.0	3.3	5.5	17.8	3.0	11.8	4.6	6.7	9.7	2.9	5.5	5.8	4.0	3.4	17.2	3.2	7.1	2.7	5.3	5.0	10.0	4.4	3.4	3.9	7.0	2.5	4.3	9.0	3.2	10.1	2.7	3.3	5.6	8.1	4.7	6.2	7.2	4.8	6.0	9.0	5.4	5.0	4.1	15.1	7.8	6.5	7.8	4.9	4.3	9.0	3.0	2.4	14.4	18.0	19.7	16.4	13.7	8.0	20.5	9.5	13.4	19.4
MITF	"bHLHe32, MI, WS2, WS2A"	ENSG00000187098	"Melanogenesis associated transcription factor"	O75030	3	69739435-69968337	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Albinism, Cancer-related genes, Deafness, Disease mutation, Microphthalmia, Osteopetrosis, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HMC-1: 26.5;SK-MEL-30: 71.3"	"Group enriched"	"Detected in all"	8	"melanoma: 39.2;renal cancer: 9.1"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basophil: 4.5;classical monocyte: 10.9;intermediate monocyte: 3.6;myeloid DC: 6.8;non-classical monocyte: 5.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 6.8;granulocytes: 4.5;monocytes: 10.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002578, HPA003259"	Enhanced									"CAB002578: AB_564111, HPA003259: AB_1079381"	"unprognostic (3.29e-1)"	"unprognostic (4.26e-2)"	"unprognostic (2.98e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.75e-1)"	"unprognostic (5.31e-3)"	"unprognostic (3.87e-3)"	"unprognostic (1.94e-1)"	"prognostic favourable (8.35e-10)"	"unprognostic (6.37e-2)"	"unprognostic (1.08e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.73e-1)"	12.8	3.8	2.6	2.6	3.9	0.8	17.8	1.7	3.0	30.6	10.1	5.9	6.4	1.5	37.9	6.2	8.3	6.4	9.9	23.4	3.1	2.4	12.8	1.8	7.1	1.7	4.2	1.1	11.1	2.4	9.7	6.2	1.8	4.0	9.0	2.5	40.1	4.0	8.2	39.1	5.8	4.1	26.2	5.0	1.8	5.1	4.7	5.1	0.1	4.4	8.1	1.0	12.1	10.3	0.0	6.8	4.5	10.9	1.4	0.1	3.4	4.8	3.3	0.3	1.5	5.6	0.1	0.6	4.9	2.8	2.2	1.4	1.7	0.2	0.0	1.1	0.0	2.6	1.0	2.7	2.5	0.0	0.6	10.7	7.1	0.1	1.4	0.2	26.5	4.6	1.1	0.6	2.5	0.7	3.5	1.5	1.6	0.2	0.1	0.3	0.2	2.4	0.0	0.5	2.3	13.4	2.5	0.2	0.5	2.5	0.9	71.3	0.2	0.6	0.0	1.1	4.0	1.6	1.0	0.1	0.2	0.0	2.3	0.7	2.8	4.5	10.9	0.0	0.0	3.6	0.0	0.0	0.0	0.1	6.8	0.0	0.0	0.0	0.7	1.4	5.7	0.5	0.0	3.4	2.6	3.9	1.7	3.0	3.1	2.4	4.2	1.1	4.0	5.1
MYC	"bHLHe39, c-Myc, MYCC"	ENSG00000136997	"MYC proto-oncogene, bHLH transcription factor"	P01106	8	127735434-127741434	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RPMI-8226: 129.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000084, CAB010307, HPA055893, HPA066556"	Approved		Enhanced	Nucleoplasm				Nucleoplasm		"CAB000084: , CAB010307: AB_631274, HPA055893: , HPA066556: "	"unprognostic (1.45e-2)"	"unprognostic (4.00e-3)"	"unprognostic (3.94e-3)"	"unprognostic (2.41e-3)"	"unprognostic (8.14e-2)"	"unprognostic (3.36e-3)"	"unprognostic (5.80e-2)"	"unprognostic (4.94e-3)"	"unprognostic (1.59e-1)"	"prognostic unfavourable (7.52e-4)"	"unprognostic (5.19e-3)"	"unprognostic (9.86e-3)"	"prognostic unfavourable (5.49e-8)"	"unprognostic (7.85e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.48e-1)"	"prognostic unfavourable (4.96e-5)"	67.4	20.8	3.2	46.6	7.1	16.3	36.0	1.2	5.0	23.9	23.3	3.8	11.8	11.1	23.8	14.4	47.6	59.5	32.4	23.7	5.8	2.2	11.2	36.6	16.0	40.5	5.8	1.2	38.7	64.6	2.1	7.4	14.9	9.8	20.6	11.3	6.1	14.4	21.8	69.6	78.5	17.2	21.3	12.0	38.3	24.7	16.3	3.8	40.2	9.0	48.4	27.1	28.9	37.3	25.5	8.8	1.0	10.3	20.9	55.2	22.0	7.1	13.8	1.2	12.3	20.0	23.7	3.6	8.6	3.7	10.7	9.0	18.8	18.7	72.9	12.0	5.1	15.5	63.9	27.8	7.1	17.2	22.3	43.9	23.4	24.5	18.4	30.7	7.0	16.5	61.5	7.2	57.0	12.3	64.8	38.6	5.3	20.5	50.1	66.8	3.4	27.6	27.9	5.2	129.7	9.0	7.4	84.9	8.0	4.0	33.5	22.2	13.6	20.2	14.9	8.1	9.6	6.2	10.7	0.7	1.2	35.2	7.1	34.3	4.0	0.7	10.3	0.1	8.6	9.1	43.4	25.5	31.1	18.6	8.8	20.6	55.2	34.8	1.0	20.9	6.1	0.3	24.8	22.0	3.2	7.1	1.2	3.6	5.8	2.2	5.8	1.2	9.8	3.8
MYCL	"bHLHe38, LMYC, MYCL1"	ENSG00000116990	"MYCL proto-oncogene, bHLH transcription factor"	P12524	1	39895426-39902256	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"pancreas: 46.4;skin 1: 26.0"	"Group enriched"	"Detected in some"	7	"U-266/70: 94.1;U-266/84: 69.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 28.9"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"classical monocyte: 11.5;intermediate monocyte: 5.5;myeloid DC: 12.9;plasmacytoid DC: 15.4"	"Group enriched"	"Detected in many"	75	"dendritic cells: 15.4;monocytes: 11.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA063132, HPA074515"			Enhanced	Nucleoplasm				Nucleoplasm		"HPA063132: , HPA074515: "	"unprognostic (7.45e-2)"	"unprognostic (6.91e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.83e-3)"	"unprognostic (1.61e-2)"	"unprognostic (2.92e-3)"	"unprognostic (6.72e-3)"	"prognostic favourable (4.49e-4)"	"unprognostic (1.24e-1)"	"unprognostic (1.77e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.12e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.75e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.53e-2)"	"unprognostic (5.80e-2)"	0.3	0.3	1.2	4.4	2.1	0.1	1.7	0.8	1.7	3.6	7.5	1.8	8.5	2.6	1.0	4.0	17.8	1.6	2.3	0.7	1.1	0.9	0.8	6.4	1.9	2.9	0.6	1.4	0.5	46.4	0.0	2.1	11.2	1.8	5.3	3.6	1.8	4.6	16.6	0.6	26.0	7.3	1.2	1.1	4.0	3.3	1.5	0.6	6.4	4.2	3.1	6.0	18.4	7.3	0.0	15.4	0.1	11.5	0.0	0.1	3.8	0.2	0.0	2.9	0.7	0.0	0.0	7.0	0.1	0.0	0.2	0.1	0.1	0.1	0.4	0.3	0.0	0.7	2.0	0.5	0.1	0.4	1.0	0.1	0.0	0.1	0.0	0.0	1.7	0.2	2.3	0.0	0.2	0.2	0.7	0.0	0.1	0.2	0.0	0.0	2.7	0.1	0.2	3.3	0.6	0.2	11.3	0.5	0.7	0.2	0.4	0.1	0.7	3.6	0.0	0.0	1.1	1.3	0.1	94.1	69.1	0.1	0.0	0.4	0.0	0.0	11.5	0.0	0.0	5.5	0.0	0.0	0.0	0.1	12.9	0.0	0.0	0.0	0.1	0.0	2.3	15.4	0.0	3.8	1.2	2.1	0.8	1.7	1.1	0.9	0.6	1.4	1.8	0.6
MYCN	"bHLHe37, MYCNOT, N-myc, NMYC"	ENSG00000134323	"MYCN proto-oncogene, bHLH transcription factor"	P04198	2	15940564-15947007	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 16.8"	"Cell line enhanced"	"Detected in some"		"AF22: 12.7;BEWO: 68.9;HMC-1: 16.6;NTERA-2: 26.1;RH-30: 18.2"	"Cancer enhanced"	"Detected in many"		"testis cancer: 45.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA057420			Approved	Nucleoplasm,Nucleoli				Nucleoli	Nucleoplasm	"HPA057420: "	"unprognostic (8.04e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.07e-2)"	"unprognostic (4.11e-1)"	"unprognostic (2.46e-2)"	"unprognostic (1.23e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.35e-3)"	"unprognostic (3.09e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.12e-3)"	"unprognostic (8.89e-2)"	"unprognostic (2.47e-1)"	"unprognostic (4.90e-2)"	"unprognostic (1.23e-1)"	0.9	1.9	5.1	1.8	5.5	1.6	1.2	1.4	8.4	3.1	1.2	12.1	0.0	3.0	1.9	0.8	1.3	1.4	2.6	2.3	7.0	4.7	6.0	1.5	1.6	2.9	6.0	2.2	10.3	0.7	0.4	0.7	16.8	6.8	0.6	1.3	1.1	6.6	0.7	1.0	2.4	1.7	0.9	8.9	0.9	8.5	6.5	4.0	5.7	5.1	2.3	3.5	2.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.7	0.0	0.0	0.0	68.9	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	26.1	0.0	0.0	18.2	3.5	0.0	0.8	0.2	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	5.5	1.4	7.0	7.0	4.7	6.0	2.2	6.8	4.0
NKX2-1	"BCH, NKX2A, TITF1, TTF-1, TTF1"	ENSG00000136352	"NK2 homeobox 1"	P43699	14	36516392-36521149	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	18	"lung: 51.5;thyroid gland: 122.8"	"Cell line enriched"	"Detected in some"	28	"SCLC-21H: 47.6"	"Group enriched"	"Detected in some"	39	"lung cancer: 30.9;thyroid cancer: 103.2"	"Group enriched"	"Detected in some"	6	"basal ganglia: 2.4;hypothalamus: 2.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"basal ganglia: 3.4;hypothalamus: 12.0"	"Group enriched"	"Detected in some"	13	"basal ganglia: 6.4;hypothalamus: 16.1"	"CAB000078, CAB053633, HPA074316"	Enhanced		Uncertain	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"CAB000078: , CAB053633: AB_442138, HPA074316: "		"unprognostic (3.79e-1)"		"unprognostic (4.25e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.79e-2)"		"unprognostic (1.26e-2)"				"unprognostic (2.23e-1)"		"unprognostic (1.18e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.83e-2)"	"unprognostic (4.18e-1)"	0.1	0.1	0.0	0.0	2.4	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	2.5	0.0	0.0	51.5	0.1	0.0	0.1	0.0	0.0	0.0	4.9	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.4	0.0	122.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	47.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.4	0.0	0.1	0.2	2.5	0.0	0.1	0.1	0.4
NSD3	"FLJ20353, KMT3F, WHISTLE, WHSC1L1"	ENSG00000147548	"Nuclear receptor binding SET domain protein 3"	Q9BZ95	8	38269697-38382272	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005659, CAB013721, HPA018893"	Uncertain		Approved	Nucleoplasm,Mitochondria				Mitochondria	Nucleoplasm	"CAB013721: , HPA005659: AB_1080596, HPA018893: AB_1858833"	"unprognostic (6.21e-2)"	"unprognostic (3.73e-2)"	"unprognostic (2.18e-2)"	"unprognostic (4.12e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.53e-2)"	"unprognostic (4.35e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.49e-1)"	"unprognostic (5.72e-2)"	"prognostic unfavourable (7.48e-4)"	"unprognostic (5.06e-2)"	"unprognostic (5.60e-3)"	"unprognostic (6.69e-2)"	"unprognostic (4.04e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.60e-2)"	19.2	11.3	31.1	15.8	31.4	36.3	20.1	51.5	37.7	18.5	15.5	16.7	14.0	16.2	16.0	12.5	17.0	16.8	17.0	12.7	24.4	16.6	14.2	11.2	17.9	22.3	25.0	26.8	26.5	16.3	21.0	24.2	22.5	21.9	16.4	18.7	12.3	18.3	17.9	12.3	16.2	17.7	16.0	15.3	17.2	19.7	9.3	25.6	16.7	19.2	6.9	20.4	19.6	23.3	26.7	5.6	26.2	5.1	8.6	18.0	2.9	23.9	13.8	23.7	16.0	16.6	19.2	17.6	20.1	22.3	17.4	20.3	7.3	13.3	28.6	18.5	13.7	14.4	18.7	16.1	24.9	11.3	11.0	36.4	11.1	8.6	17.1	16.0	13.2	10.3	16.4	15.7	32.1	20.0	25.8	19.0	16.5	8.6	46.7	13.6	16.1	6.5	21.4	25.9	9.0	12.4	18.6	13.4	18.1	16.3	14.3	14.0	18.1	12.2	19.0	18.2	18.9	27.0	11.8	17.0	20.2	27.6	15.3	16.2	13.1	13.9	5.1	9.1	8.0	2.4	5.3	16.5	12.0	7.1	4.1	26.7	15.0	6.3	26.2	8.6	1.5	5.6	18.0	2.9	31.1	31.4	51.5	37.7	24.4	16.6	25.0	26.8	21.9	25.6
NTRK1	"MTC, TRK, TRKA"	ENSG00000198400	"Neurotrophic receptor tyrosine kinase 1"	P04629	1	156815640-156881850	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"adrenal gland: 15.8;blood: 32.3;brain: 28.3"	"Cell line enriched"	"Detected in some"	4	"HMC-1: 41.1"	"Cancer enhanced"	"Detected in some"		"glioma: 1.3"	"Region enriched"	"Detected in many"	5	"pons and medulla: 28.3"	"Cell type enriched"	"Detected in single"	127	"basophil: 32.3"	"Lineage enriched"	"Detected in single"	323	"granulocytes: 32.3"	"Region enhanced"	"Detected in some"		"basal ganglia: 8.2"	"Low region specificity"	"Detected in all"			"CAB004606, HPA035799, HPA076570"	Approved		Approved	Vesicles,Cytosol			140000	"Vesicles, Cytosol"		"CAB004606: AB_628397, HPA035799: , HPA076570: "	"unprognostic (5.89e-3)"	"unprognostic (7.56e-2)"	"unprognostic (2.74e-2)"	"unprognostic (5.99e-3)"	"unprognostic (7.26e-2)"	"unprognostic (1.43e-3)"	"unprognostic (1.56e-1)"	"unprognostic (7.42e-3)"	"unprognostic (7.63e-2)"	"unprognostic (1.35e-1)"	"unprognostic (6.73e-2)"	"unprognostic (2.29e-2)"	"unprognostic (3.18e-11)"	"unprognostic (2.18e-3)"	"unprognostic (3.79e-2)"	"unprognostic (1.07e-1)"	"unprognostic (4.89e-1)"	1.0	15.8	0.5	0.8	6.0	0.9	0.4	0.0	0.7	0.9	1.1	0.1	0.0	0.8	1.6	2.0	0.7	0.6	2.1	1.5	0.0	1.2	2.9	0.2	1.9	0.3	2.1	0.6	0.3	0.3	0.3	1.1	0.5	28.3	2.2	0.2	3.1	1.2	0.5	0.7	0.2	0.4	1.1	1.2	0.2	1.0	2.4	1.5	0.4	0.3	0.0	0.4	0.7	0.8	0.0	0.0	32.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	5.6	0.0	6.6	0.0	0.0	0.0	0.0	41.1	0.0	0.0	0.0	0.0	0.0	2.1	0.7	0.0	0.0	0.0	1.1	0.0	0.6	1.2	0.0	0.1	0.0	0.0	0.7	9.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	1.6	0.2	0.0	0.0	0.0	0.0	32.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.0	0.0	0.6	0.0	1.2	2.1	0.6	28.3	1.5
PPM1D	"PP2C-DELTA, Wip1"	ENSG00000170836	"Protein phosphatase, Mg2+/Mn2+ dependent 1D"	O15297	17	60600183-60666280	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle"	"Hydrolase, Protein phosphatase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 26.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA022277	Approved		Approved	"Endoplasmic reticulum"				"Endoplasmic reticulum"		"HPA022277: AB_1858839"	"unprognostic (1.48e-1)"	"unprognostic (1.36e-2)"	"prognostic favourable (3.52e-4)"	"unprognostic (1.76e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.12e-2)"	"prognostic unfavourable (4.27e-4)"	"unprognostic (5.50e-2)"	"unprognostic (1.70e-2)"	"unprognostic (6.07e-2)"	"unprognostic (2.52e-3)"	"unprognostic (3.46e-2)"	"unprognostic (1.95e-3)"	"unprognostic (7.33e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.98e-1)"	12.2	7.0	6.1	5.7	9.2	13.6	11.9	30.8	6.6	11.1	10.0	10.6	7.8	7.6	12.0	8.3	8.6	11.1	8.3	5.8	7.7	4.4	7.4	7.4	9.2	7.9	10.3	4.6	17.3	12.3	8.1	8.9	18.5	8.8	9.3	9.4	8.2	8.1	6.8	9.7	8.1	8.1	8.2	7.3	9.2	7.3	16.2	12.5	15.5	8.7	6.9	7.0	7.8	11.3	7.3	13.1	20.5	13.2	6.8	8.3	6.8	2.7	5.4	6.1	5.2	4.1	2.5	7.9	4.3	2.8	2.8	4.0	5.5	1.6	7.8	3.5	2.9	2.9	3.9	1.8	3.8	1.4	8.7	5.6	5.4	6.4	3.4	2.2	4.3	2.2	2.9	4.1	2.4	6.3	4.1	3.3	3.0	26.5	6.1	3.4	2.6	4.2	7.4	7.8	4.7	2.5	3.4	8.4	6.1	5.7	1.9	1.3	2.3	3.0	4.6	3.6	10.0	2.8	2.3	5.3	5.6	5.9	1.4	2.3	2.8	8.2	13.2	14.1	6.7	10.2	5.9	7.3	5.6	6.1	13.1	5.9	6.1	6.2	20.5	6.8	6.1	5.8	8.3	6.8	6.1	9.2	30.8	6.6	7.7	4.4	10.3	4.6	8.8	12.5
RAF1	"c-Raf, CRAF, Raf-1"	ENSG00000132155	"Raf-1 proto-oncogene, serine/threonine kinase"	P04049	3	12583601-12664226	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 53.9"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 53.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002640, CAB019291"	Approved		Approved	"Nuclear speckles"				"Nuclear speckles"		"CAB019291: , HPA002640: AB_1856047"	"unprognostic (6.33e-2)"	"unprognostic (1.29e-1)"	"unprognostic (5.92e-2)"	"unprognostic (2.17e-3)"	"unprognostic (6.51e-3)"	"unprognostic (7.66e-3)"	"unprognostic (2.66e-3)"	"unprognostic (1.53e-2)"	"unprognostic (2.72e-1)"	"unprognostic (7.66e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.64e-2)"	"unprognostic (2.36e-2)"	19.5	15.6	15.1	14.7	17.1	32.2	17.5	35.2	18.9	19.9	20.3	21.1	19.6	18.4	24.9	15.7	24.6	18.6	20.2	39.3	15.3	11.0	21.7	36.2	19.7	15.7	16.0	13.4	24.9	31.3	30.7	16.9	24.8	14.3	18.8	19.2	25.0	18.3	18.4	79.7	23.9	29.6	23.7	13.8	22.1	23.7	16.7	17.8	27.7	26.9	27.9	26.1	20.5	20.4	6.6	9.3	53.9	9.9	8.5	8.6	7.7	15.1	17.4	26.6	20.5	23.1	18.7	53.5	23.1	39.2	30.6	34.8	13.6	12.5	15.9	11.1	35.8	9.7	28.0	20.5	31.9	27.7	21.9	21.4	21.0	12.6	23.4	20.8	20.3	17.2	20.7	31.5	25.6	21.9	15.5	41.8	29.5	25.9	26.7	15.3	27.0	23.7	21.6	23.4	20.0	18.3	22.9	8.3	17.5	18.9	18.3	12.3	30.4	27.5	15.7	21.1	20.1	17.6	25.7	32.6	51.8	34.2	18.2	24.3	22.4	11.3	9.7	18.4	7.4	9.9	7.5	6.6	7.3	7.2	9.3	6.3	7.5	7.6	53.9	8.5	9.6	4.2	8.6	7.7	15.1	17.1	35.2	18.9	15.3	11.0	16.0	13.4	14.3	17.8
REL	"c-Rel, I-Rel"	ENSG00000162924	"REL proto-oncogene, NF-kB subunit"	Q04864	2	60881521-60931610	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 26.6;U-698: 51.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB004404	Uncertain									"CAB004404: AB_670194"	"unprognostic (2.77e-1)"	"unprognostic (2.05e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.23e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.15e-2)"	"unprognostic (2.15e-1)"	"unprognostic (5.87e-2)"	"unprognostic (4.38e-2)"	"unprognostic (4.37e-1)"	"unprognostic (2.82e-2)"	"unprognostic (2.91e-2)"	"unprognostic (3.53e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.66e-2)"	11.2	4.7	3.5	25.9	5.4	35.1	7.7	9.8	5.0	9.7	8.4	4.3	6.2	4.8	8.7	6.6	11.9	6.9	10.1	5.7	3.2	3.1	4.5	8.0	20.5	15.3	5.5	1.8	13.3	7.1	10.8	9.1	6.3	4.7	10.8	5.3	6.0	7.9	6.9	5.0	14.2	9.3	7.7	10.6	22.5	6.0	5.0	5.2	15.3	7.2	6.4	23.8	21.3	14.1	20.8	9.5	11.2	12.9	6.5	7.2	5.5	3.0	1.8	1.4	1.8	1.1	1.1	3.1	1.0	1.6	1.0	1.2	1.3	2.6	26.6	2.6	0.9	3.6	2.4	1.7	2.1	7.2	2.4	2.7	2.8	1.4	0.6	5.3	3.2	1.0	4.6	2.1	3.3	2.4	3.5	1.7	0.7	1.6	3.8	2.1	1.7	0.7	5.4	3.9	1.1	1.1	12.0	1.3	1.5	3.0	3.3	0.9	1.9	2.3	2.6	2.2	2.5	1.5	1.5	2.3	1.0	51.6	1.3	4.6	1.1	6.5	9.6	6.0	7.2	10.9	5.0	14.4	3.8	5.5	9.5	20.8	2.4	5.4	11.2	6.5	12.9	6.7	4.6	5.5	3.5	5.4	9.8	5.0	3.2	3.1	5.5	1.8	4.7	5.2
SOX2		ENSG00000181449	"SRY-box 2"	P48431	3	181711924-181714436	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 80.1"	"Cell line enhanced"	"Detected in some"		"AF22: 67.5;HAP1: 28.7;NTERA-2: 55.0;U-251 MG: 12.6"	"Cancer enhanced"	"Detected in many"		"glioma: 136.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045725, HPA062851, HPA071379, CAB079745"	Enhanced	Supported	Enhanced	Nucleoplasm				Nucleoplasm		"CAB079745: , HPA045725: , HPA062851: , HPA071379: "	"unprognostic (1.80e-2)"	"unprognostic (3.18e-3)"	"unprognostic (5.69e-2)"	"unprognostic (6.96e-2)"	"unprognostic (2.74e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.79e-2)"	"unprognostic (4.48e-3)"	"unprognostic (1.71e-1)"	"unprognostic (4.38e-3)"	"unprognostic (1.83e-1)"	"unprognostic (7.68e-2)"	"unprognostic (3.81e-9)"	"unprognostic (1.12e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.12e-2)"	1.8	2.5	30.3	2.0	25.8	1.5	1.6	13.9	80.1	1.8	2.3	24.3	0.0	2.0	1.5	1.8	15.9	5.0	1.8	1.7	36.0	19.2	1.5	1.5	3.4	1.5	19.4	18.5	1.7	1.6	1.5	5.8	1.5	18.6	3.9	2.0	1.0	6.3	1.9	1.6	1.8	2.3	1.7	18.4	1.6	9.7	3.0	22.4	0.0	1.5	2.1	6.9	2.3	1.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.1	67.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.1	28.7	0.7	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	55.0	0.1	0.0	0.1	0.0	7.4	0.1	0.1	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	12.6	0.0	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.3	25.8	13.9	20.0	36.0	19.2	19.4	18.5	18.6	22.4